Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz

Novartis AG said it is considering the sale or spinoff of its generic drugs business Sandoz, a move that would focus the once-sprawling healthcare conglomerate solely on innovative prescription drugs.

Sandoz, like many generic drugmakers, has struggled with falling prices in the U.S. in recent years. Generic drugs are lower-cost versions of prescription medicines whose patents have expired. While their prices are usually far below those of the branded drugs that they imitate, increased competition has driven those prices even lower in recent years.

Source

Leave a Reply

Your email address will not be published. Required fields are marked *

scroll to top